Opus Genetics (IRD) EBT Margin (2010 - 2026)
Opus Genetics (IRD) posted quarterly EBT Margin of 3038.25% for Q1 2026, down 285074.0% year-over-year from N/an in Q1 2025, and down 610.7% quarter-over-quarter from 427.5% in Q4 2025.
Opus Genetics (IRD) EBT Margin (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported EBT Margin for 8 consecutive years, with 3038.25% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 285074.0% year-over-year to 3038.25%; the TTM figure through Mar 2026 stood at 892.36% (down 46295.0% YoY), while the FY2025 annual figure was 349.33%, up 17407.0% from the prior year.
- EBT Margin fell to 3038.25% in Q1 2026 per IRD's latest filing, from 427.5% in the prior quarter.
- Across five years, EBT Margin topped out at 85.96% in Q4 2022 and bottomed at 3038.25% in Q1 2026.
- Historically, EBT Margin has averaged 515.69% across 5 years, with a median of 307.39% in 2023.
- Annual changes were most pronounced in 2025 — EBT Margin jumped 44083 bps — and 2026, when it tumbled 285074 bps.
- Opus Genetics' EBT Margin stood at 85.96% in 2022, then slumped by 430 bps to 283.68% in 2023, then slumped by 188 bps to 816.71% in 2024, then jumped by 48 bps to 427.5% in 2025, then slumped by 611 bps to 3038.25% in 2026.
- Business Quant data shows IRD's EBT Margin at 3038.25% in Q1 2026, 427.5% in Q4 2025, and 566.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -1,072.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,072.58% |
| Mar 31, 2026 | -3,038.25% |
| Dec 31, 2025 | -427.50% |
| Sep 30, 2025 | -566.87% |
| Jun 30, 2025 | -257.46% |
| Mar 31, 2025 | -187.51% |
| Dec 31, 2024 | -816.71% |
| Sep 30, 2024 | -194.62% |
| Jun 30, 2024 | -698.29% |
| Mar 31, 2024 | -415.31% |
| Dec 31, 2023 | -283.68% |
| Sep 30, 2023 | 46.71% |
| Jun 30, 2023 | -135.03% |
| Mar 31, 2023 | -331.10% |
| Dec 31, 2022 | 85.96% |
| Sep 30, 2021 | -865.03% |
| Jun 30, 2021 | -7,136.00% |
| Mar 31, 2020 | -268.52% |
| Jun 30, 2010 | -19,184.37% |